What is DVT?

DVT occurs when a blood clot forms in one of the large veins, usually in the legs, leading to either partially or completely blocked circulation. If left untreated, this clot has the potential to move into the lungs and produce a pulmonary embolism requiring immediate medical attention.

Who is at risk?

DVT is an equal opportunity killer. It does not discriminate by age, race, or gender. Anyone can be affected under the right circumstances, even if they are otherwise healthy and active. DVT threatens nearly two million Americans each year. DVT risk is greatest between two and five days after surgery, with a second peak risk period occurring about 10 days after surgery— usually after the patient has been discharged. Although preventable, almost 100,000 people die annually from DVT and its primary complication, pulmonary embolism.

The National Impact of Blood Clots


People Affected Each Year

Venous thomboembolism (VTE) affects as many as 900,000 Americans each year


People Die Each Year

As many as 100,000 people die of blot clots each year

1 in 4

Sudden Deaths

1 in 4 people who have a pulmonary embolism (PE) die without warning

5x the risk

During Pregnancy

Women are five times more likely to experience a dangerous blood clot when they are pregnant

2x the risk

C-section Delivery

Surgical delivery by C-section nearly doubles a pregnant woman’s risk for dangerous blood clots

1 in 10

Hospital Deaths

Roughly 1 out of 10 hospital deaths are related to blood clots in the lungs

How to Prevent DVT?

Sequential Compression Device
A Sequential Compression Device (SCD) is a method of  DVT prevention that improves blood flow in the legs. SCD’s are shaped like “sleeves” that wrap around the legs and inflate with air one at a time. This imitates walking and helps prevent blood clots. SCD's should be worn anytime a patient is in bed or sitting.

Scientific and clinical evaluations of SCD's strongly suggest that the nature of their effect on DVT prophylaxis derives from their ability to increase mean and peak femoral vein (in the leg) velocity, in addition to their effect on the systemic coagulation and fibrinolytic mechanisms.

ManaMed PlasmaFlow

The Gold Standard of Prevention
PlasmaFlow, introduced by ManaMed Inc. in 2017, was the world's first FDA-Approved digital & tubeless DVT Prevention device.

Prevention made simple.
PlasmaFlow product image

Get back to doing
what you love.